{"id":"https://openalex.org/W4416900413","doi":"https://doi.org/10.1158/1535-7163.30761260","title":"Supplementary Figure 1 from Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death","display_name":"Supplementary Figure 1 from Trametinib Thwarts Activation of Survival Pathways Induced by Pro-ferroptotic Drug Conjugate ACXT-3102 Resulting in Enhanced Pancreatic Cancer Cell Death","publication_year":2025,"publication_date":"2025-12-02","ids":{"openalex":"https://openalex.org/W4416900413","doi":"https://doi.org/10.1158/1535-7163.30761260"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.30761260","doi":"https://doi.org/10.1158/1535-7163.30761260","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.30761260","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Trametinib_Thwarts_Activation_of_Survival_Pathways_Induced_by_Pro-ferroptotic_Drug_Conjugate_ACXT-3102_Resulting_in_Enhanced_Pancreatic_Cancer_Cell_Death/30761260/1/files/60032494.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Trametinib_Thwarts_Activation_of_Survival_Pathways_Induced_by_Pro-ferroptotic_Drug_Conjugate_ACXT-3102_Resulting_in_Enhanced_Pancreatic_Cancer_Cell_Death/30761260/1/files/60032494.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5077968110","display_name":"Kumar S. Bishnupuri","orcid":"https://orcid.org/0000-0002-7119-6923","observed_orcids":["https://orcid.org/0000-0002-7119-6923"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kumar S. Bishnupuri","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7119-6923","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078894708","display_name":"Kenneth F. Newcomer","orcid":"https://orcid.org/0000-0002-7034-498X","observed_orcids":["https://orcid.org/0000-0002-7034-498X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kenneth F. Newcomer","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-7034-498X","affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Qingqing Gong","orcid":"https://orcid.org/0009-0005-9452-0203","observed_orcids":["https://orcid.org/0009-0005-9452-0203"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Qingqing Gong","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-9452-0203","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070529929","display_name":"Rony Takchi","orcid":"https://orcid.org/0000-0002-6854-0674","observed_orcids":["https://orcid.org/0000-0002-6854-0674"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rony Takchi","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6854-0674","affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Li Ye","orcid":"https://orcid.org/0009-0006-6898-1222","observed_orcids":["https://orcid.org/0009-0006-6898-1222"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Li Ye","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0006-6898-1222","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046107872","display_name":"Suwanna Vangveravong","orcid":"https://orcid.org/0009-0006-5997-0687","observed_orcids":["https://orcid.org/0009-0006-5997-0687","https://orcid.org/0000-0002-5098-8024"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Suwanna Vangveravong","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0006-5997-0687","affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Lauren Ross","orcid":"https://orcid.org/0009-0004-3406-4210","observed_orcids":["https://orcid.org/0009-0004-3406-4210"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lauren Ross","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-3406-4210","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003432789","display_name":"Brian Andrew Van Tine","orcid":"https://orcid.org/0000-0003-4572-6668","observed_orcids":["https://orcid.org/0000-0003-4572-6668"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brian A. Van Tine","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4572-6668","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060050760","display_name":"William G. Hawkins","orcid":"https://orcid.org/0000-0001-7087-3585","observed_orcids":["https://orcid.org/0000-0001-7087-3585"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William G. Hawkins","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7087-3585","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5013020518","display_name":"Dirk Spitzer","orcid":"https://orcid.org/0000-0003-3949-1815","observed_orcids":["https://orcid.org/0000-0003-3949-1815"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dirk Spitzer","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3949-1815","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11297","display_name":"Ferroptosis and cancer prognosis","score":0.9639000296592712,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11297","display_name":"Ferroptosis and cancer prognosis","score":0.9639000296592712,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.029600000008940697,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trametinib","display_name":"trametinib","score":0.8029999732971191},{"id":"https://openalex.org/keywords/ferroptosis","display_name":"ferroptosis","score":0.8949999809265137},{"id":"https://openalex.org/keywords/pancreatic-ductal-adenocarcinoma","display_name":"pancreatic ductal adenocarcinoma","score":0.9269999861717224},{"id":"https://openalex.org/keywords/ferrostatin-1","display_name":"ferrostatin-1","score":0.8209999799728394},{"id":"https://openalex.org/keywords/deferoxamine","display_name":"deferoxamine","score":1.0},{"id":"https://openalex.org/keywords/cell-viability","display_name":"cell viability","score":0.7570000290870667},{"id":"https://openalex.org/keywords/bxpc-3-cells","display_name":"BxPC-3 cells","score":0.8119999766349792},{"id":"https://openalex.org/keywords/aspc-1","display_name":"AsPC-1","score":0.9990000128746033},{"id":"https://openalex.org/keywords/panc-1-cells","display_name":"PANC-1 cells","score":0.9169999957084656},{"id":"https://openalex.org/keywords/cell-death","display_name":"cell death","score":0.5730000138282776}],"concepts":[{"id":"https://openalex.org/C2778472372","wikidata":"https://www.wikidata.org/wiki/Q7833138","display_name":"Trametinib","level":4,"score":0.881600022315979},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6858000159263611},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6697999835014343},{"id":"https://openalex.org/C31573885","wikidata":"https://www.wikidata.org/wiki/Q304484","display_name":"Programmed cell death","level":3,"score":0.5925999879837036},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.5633000135421753},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4681999981403351},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.445499986410141},{"id":"https://openalex.org/C3019137385","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell survival","level":3,"score":0.42419999837875366},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4081999957561493},{"id":"https://openalex.org/C169382597","wikidata":"https://www.wikidata.org/wiki/Q21208025","display_name":"Programmed cell death 1","level":5,"score":0.4000000059604645},{"id":"https://openalex.org/C197336794","wikidata":"https://www.wikidata.org/wiki/Q5161150","display_name":"Conjugate","level":2,"score":0.367000013589859},{"id":"https://openalex.org/C2776672577","wikidata":"https://www.wikidata.org/wiki/Q419618","display_name":"Deferoxamine","level":2,"score":0.3474000096321106},{"id":"https://openalex.org/C144745244","wikidata":"https://www.wikidata.org/wiki/Q4927286","display_name":"Blocking (statistics)","level":2,"score":0.34290000796318054},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.34220001101493835},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.33959999680519104},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.33730000257492065},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.3215000033378601},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.3158000111579895},{"id":"https://openalex.org/C3019816032","wikidata":"https://www.wikidata.org/wiki/Q2575340","display_name":"Cancer treatment","level":3,"score":0.29179999232292175},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2858999967575073},{"id":"https://openalex.org/C2994372470","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell lines","level":4,"score":0.26840001344680786},{"id":"https://openalex.org/C53227056","wikidata":"https://www.wikidata.org/wiki/Q189152","display_name":"Viability assay","level":3,"score":0.25369998812675476}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.30761260","doi":"https://doi.org/10.1158/1535-7163.30761260","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.30761260","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Trametinib_Thwarts_Activation_of_Survival_Pathways_Induced_by_Pro-ferroptotic_Drug_Conjugate_ACXT-3102_Resulting_in_Enhanced_Pancreatic_Cancer_Cell_Death/30761260/1/files/60032494.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/30761260","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Trametinib_Thwarts_Activation_of_Survival_Pathways_Induced_by_Pro-ferroptotic_Drug_Conjugate_ACXT-3102_Resulting_in_Enhanced_Pancreatic_Cancer_Cell_Death/30761260","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.30761260","doi":"https://doi.org/10.1158/1535-7163.30761260","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.30761260","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_1_from_Trametinib_Thwarts_Activation_of_Survival_Pathways_Induced_by_Pro-ferroptotic_Drug_Conjugate_ACXT-3102_Resulting_in_Enhanced_Pancreatic_Cancer_Cell_Death/30761260/1/files/60032494.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4416900413.pdf"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4411974213","https://openalex.org/W7108208602","https://openalex.org/W4393072746","https://openalex.org/W4312854592","https://openalex.org/W4387422795","https://openalex.org/W4205450164","https://openalex.org/W2990602563","https://openalex.org/W4286218471","https://openalex.org/W7120880889","https://openalex.org/W2787640879"],"abstract_inverted_index":{"Cell":[0],"viability":[1],"assays":[2],"exhibiting":[3],"ferrostatin-1":[4],"and":[5,18],"deferoxamine":[6],"(ferroptosis-specific":[7],"inhibitors)-mediated":[8],"blocking":[9],"of":[10],"ACXT-3102-induced":[11],"cell":[12],"death":[13],"in":[14],"PDAC":[15],"(BxPC-3,":[16],"AsPC-1,":[17],"PANC-1)":[19],"cells.":[20]},"counts_by_year":[],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2025-12-02T00:00:00"}